Full Citation
Title: 0546 Sleep Medication Use Trajectories over 30 Years and Late-Life Hearing Loss
Citation Type: Journal Article
Publication Year: 2025
ISBN:
ISSN: 0161-8105
DOI: 10.1093/SLEEP/ZSAF090.0546
NSFID:
PMCID:
PMID:
Abstract: SLEEP, Volume 48, Supplement 1, 2025 95%CI=0.53,0.68; p< 0.0001], and control [HR=0.68, 95%CI=0.60,0.77; p< 0.0001]. Similarly, TCA was associated with lower mortality risk compared to Z-drugs [HR=0.90, 95%CI=0.88,0.93; p< 0.0001], MLT [HR=0.71, 95%CI=0.69, 0.73; p< 0.0001], BNZ [HR=0.86, 95%CI=0.83, 0.88; p< 0.0001], and control [HR=0.86, 95%CI=0.84,0.88; p< 0.0001]. Z-drugs were associated with lower mortality risk compared to MLT [HR=0.77, 95%CI=0.74, 0.77; p< 0.0001], and BNZ [HR=0.93, 95%CI=0.92,0.95; p< 0.0001] but no difference to control [HR=0.99, 95%CI=0.98, 1.02; p=0.915]. However, treatment with MLT or BNZ was associated with an increased mortality risk compared to control [HR=1.27, 95%CI=1.25,1.29; p< 0.0001], [HR=1.06, 95%CI= 1.05,1.08; p< 0.0001], respectively. MLT was associated with higher mortality risk compared to BNZ [HR=1.19, 95%CI=1.18,1.21; p< 0.0001]. Conclusion: In this retrospective study, treatment with orexin receptor agonists was associated with a more favorable survival compared to other insomnia medications in patients with HF and insomnia. Future randomized controlled studies are warranted to confirm these findings. Introduction: Evidence regarding the potential adverse impact of sleep medications on hearing is inconsistent and limited. Potential mechanisms include decreased input from the auditory nerve and disturbed organization and integration of sensory information. This study aims to investigate the associations between trajectories of sleep medication use over nearly 30 years and late-life hearing among community-dwelling adults. Methods: Participants in the Atherosclerosis Risk in Communities (ARIC) Study underwent hearing evaluations at visit 6 (2016-17) and provided medications used in the past four weeks for each visit from visits 1 (1987-89) to 6. Hearing outcomes included: (1) Peripheral auditory function: better-ear four-frequency (0.5, 1, 2, 4 kHz) pure-tone average (PTA, higher=worse) assessed by pure-tone audiometry in decibels (dB); (2) Central auditory function: Quick Speech-in-noise (QuickSIN) test measures the ability to understand speech in noise, with score ranging from 0-30
Url: https://dx.doi.org/10.1093/sleep/zsaf090.0546
User Submitted?: No
Authors: Jiang, Kening; Deal, Jennifer; Liu, Chunyu; Kaizi-Lutu, Marc; Lee, Angel; Full, Kelsie; Lutsey, Pamela; Morales, Emmanuel Garcia; Punjabi, Naresh; Reed, Nicholas; Wu, Mark; Lin, Frank; Gottesman, Rebecca; Spira, Adam; Hopkins Bloomberg, Johns
Periodical (Full): Sleep
Issue: Supplement_1
Volume: 48
Pages: A238-A238
Countries: